Motorcycle Accident and Pharmacy Lien: A Case Study

James Wong — Founder & Pharmacist, LienScripts | February 10, 2026 | 8 min read

An uninsured motorcyclist T-boned at an intersection sustained a femur fracture, AC joint separation, mTBI, and road rash requiring 14 months of pharmacy lien coverage across seven concurrent medications — with a failed gabapentin taper at month 10 proving ongoing medical necessity.

Overview

This case study follows the pharmacy lien treatment arc for a 31-year-old motorcyclist struck by a vehicle that ran a red light. The patient carried no health insurance and had no MedPay coverage on his motorcycle policy. Without a pharmacy lien, he would have been unable to fill any of his injury-related prescriptions from day one.

Disclaimer: This case study is a fictionalized composite created for educational purposes. It does not represent any specific patient, case, or outcome.

Case Background

Patient: Marcus, 31-year-old rideshare driver Accident: T-bone collision — vehicle ran red light, struck Marcus broadside at approximately 35 mph Initial diagnoses: Right femur shaft fracture (intramedullary nail fixation), Grade III AC joint separation (right shoulder), mild traumatic brain injury, extensive road rash (right arm and leg) Insurance at time of accident: Minimum liability motorcycle policy (no MedPay, no health insurance) Attorney referral: Day 3 post-accident Pharmacy lien enrollment: Day 4

The Medical Picture

Motorcycle accidents consistently produce some of the most medically complex pharmacy lien cases. When a rider goes down at speed, the body absorbs force across multiple regions simultaneously — unlike a restrained occupant in a vehicle.

Marcus's femur fracture required intramedullary nailing, a surgical procedure placing a rod through the femoral canal to stabilize the bone. Typical recovery time for this injury is 4–6 months of active management and 12+ months before full functional return. His Grade III AC separation — a complete rupture of the acromioclavicular ligament — required immobilization and eventually surgical repair at month 5.

The mTBI introduced a third treatment track that ran independently from the orthopedic injuries. Marcus experienced post-concussive headaches, photosensitivity, cognitive fog, and sleep disruption. The neurologist initiated levetiracetam prophylactically given the concussive mechanism. As the acute phase resolved, the headache pattern shifted to a post-traumatic migraine syndrome requiring sumatriptan.

Road rash, while often dismissed as minor, required a compounded topical formulation to manage the neuropathic burning across the extensive abraded surfaces. Standard oral medications were inadequate for localized neuropathic skin pain without the systemic side effects of gabapentin at the doses that would have been needed.

Pharmacy Lien Medication Arc

Phase 1 — Acute Hospitalization and Discharge (Weeks 1–4)

• Oxycodone for post-surgical femur pain (2-week course, tapering)
• Celecoxib as the anti-inflammatory bridge post-taper
• Methocarbamol for hip and shoulder spasm
• Levetiracetam 500 mg BID — mTBI seizure prophylaxis
• Compounded topical (ketamine 10%/lidocaine 5%/menthol 2% cream) — road rash neuropathic pain

[!KEY] Levetiracetam and the compounded topical both represent medications that standard health insurance plans frequently deny for personal injury indications — levetiracetam because the prophylactic indication is off-label for non-epileptic mTBI, and compounded topicals because most plans exclude compounded formulations entirely. The pharmacy lien filled both without a prior authorization battle.

Phase 2 — Subacute Recovery and AC Repair (Months 2–6)

• Gabapentin 300 mg TID — initiated at month 2 when post-concussive nerve pain clarified as a distinct syndrome from headache
• Sumatriptan 50 mg — added at month 3 as post-traumatic migraines differentiated from general post-concussive headaches
• Celecoxib continued through AC joint surgical repair (month 5) with post-surgical dose increase
• Trazodone 50 mg — added at month 4 for sleep disruption and low-grade depression emerging in the subacute period

[!SOURCE] Post-traumatic headache is among the most common sequelae of mild TBI. A systematic review published in Cephalalgia (PMID: 24493654) found that triptans are effective for post-traumatic migraine when the headache meets International Headache Society criteria for migraine — a finding frequently used to support medical necessity in PI demand packages.

Phase 3 — Chronic Management and Taper Attempts (Months 7–14)

At month 7, the prescribing pain management physician initiated a gabapentin taper attempt as Marcus appeared to plateau. The taper from 300 mg TID to 200 mg TID was tolerated for 6 weeks. At month 10, the physician attempted a further reduction to 100 mg TID.

The month 10 taper failed. Marcus reported significant return of neuropathic leg and arm pain, sleep disruption worsening, and migraine frequency increasing from 2-3 per month to 6-8 per month within three weeks of the dose reduction. The physician returned him to 300 mg TID and documented the failed taper explicitly: "Attempted gabapentin reduction unsuccessful. Symptom exacerbation on dose reduction confirms ongoing neuropathic pain dependence on current regimen. No further taper attempts planned pending neurological re-evaluation."

This documentation became one of the most important medical necessity arguments in the demand package. Defense counsel's IME physician had opined at month 9 that Marcus had reached maximum medical improvement and that ongoing gabapentin use was not causally related to the accident. The physician note documenting the failed taper — generated one month after the IME — directly rebutted this opinion.

[!KEY] A failed medication taper documented in the medical record is powerful evidence of ongoing medical necessity. It demonstrates that the prescribing physician attempted to reduce the patient's medication burden and that the patient's symptoms substantively worsened, confirming continued dependence on the medication for accident-related injury management.

Final active medications at month 14 (case settlement):

• Gabapentin 300 mg TID (returned to full dose after failed taper)
• Sumatriptan as needed (averaging 3 fills per month throughout case)
• Trazodone 50 mg nightly
• Celecoxib 200 mg daily (post-AC repair maintenance)

MERIT Report and Settlement

The MERIT report was generated at month 13 in anticipation of settlement demand. It documented:

• 14-month continuous fill history across all seven medications (no fill gaps)
• Month-by-month sumatriptan utilization trend (filling 2-4 tablets/month initially, stabilizing at 6-9/month from month 5 onward — correlating with the post-traumatic migraine diagnosis)
• Complete documentation of the gabapentin taper attempt, failure, and return to full dose
• Medication categories broken down by injury system (orthopedic: celecoxib; mTBI/neurological: levetiracetam, gabapentin, sumatriptan; psychological: trazodone; neuropathic wound: compounded topical)

[!KEY] Sumatriptan utilization trends are particularly persuasive in mTBI cases. An escalating fill pattern over months 3–6 followed by sustained, predictable fills at months 7–14 creates a visual timeline of migraine syndrome development and stabilization — exactly the pattern a genuine post-traumatic migraine diagnosis would produce. Random or inconsistent fills, by contrast, invite challenge.

The at-fault driver carried a $100,000 per-person liability policy. The policy was tendered at month 9 prior to resolution. Marcus's attorney pursued the at-fault driver's umbrella policy, which added $1,000,000 in coverage. The MERIT report, combined with surgical records and the neurologist's mTBI documentation, supported the demand against the umbrella carrier. The case settled at month 14. The pharmacy lien was paid in full from the net settlement proceeds.

What This Case Illustrates

Multiple concurrent injury tracks create a complex but valuable pharmacy record. When orthopedic, neurological, and psychological medications all run simultaneously, the MERIT shows a multi-system injury picture that reflects the true severity of a high-impact accident.

Taper failures are medical necessity gold. The month 10 failed gabapentin taper — documented by the treating physician — neutralized the IME opinion and confirmed ongoing necessity at exactly the moment defense would have argued maximum improvement.

Uninsured patients need the lien most. Marcus had zero fallback coverage. Without the pharmacy lien, he would have gone without medications that were critical both to his recovery and to building the evidentiary record that supported a seven-figure demand.

Related Resources

• What Is a Pharmacy Lien?
• Pain Management After a Car Accident
• Gabapentin vs. Pregabalin for Personal Injury
• Case Study: Commercial Truck Accident
• Levetiracetam After TBI: Pharmacy Lien Guide